Cigna's SWOT analysis: healthcare giant navigates stop-loss challenges

Cigna Group (CI) faces near-term headwinds in its stop-loss business, which led to a downward revision of its 2025 EPS growth guidance to 7.9%, despite a strong Q1 2025 performance driven by its Cigna Healthcare segment; however, the company is strategically focusing on its Evernorth segment, including specialty pharmacy, and has a substantial $7.7 billion buyback authorization, indicating confidence in long-term growth and shareholder value, with analysts projecting a FY25 EPS of $29.69.

Analysis

Cigna Group (CI) is navigating a complex period characterized by near-term operational challenges in its stop-loss business, counterbalanced by strategic growth initiatives in its Evernorth segment, particularly specialty pharmacy. The company's Q4 2024 earnings were significantly impacted by increased incidence and severity of high-cost claims in the stop-loss segment, leading to a revised, lower full-year 2025 EPS growth guidance of 7.9%, down from the previously anticipated 10% or more. However, Cigna demonstrated resilience with a strong Q1 2025 EPS beat, primarily driven by its Cigna Healthcare segment's premium growth and an improved medical loss ratio (MLR) of 82.2%, approximately 80 basis points better than anticipated. Strategically, Cigna has streamlined operations by divesting its Medicare business and maintains no Medicaid exposure, a move considered advantageous in the current political climate, allowing focus on core competencies such as the Select employer segment. Management is actively addressing the stop-loss issues, a turnaround expected to span up to two pricing cycles, while simultaneously investing in the long-term growth pipeline of Evernorth and its specialty pharmacy businesses, Accredo and CuraScript. The company's financial position remains robust, evidenced by a 'GREAT' Financial Health Score of 3.14 from InvestingPro and a substantial $7.7 billion share repurchase authorization as of May 2025, alongside a 44-year history of dividend payments yielding 1.9%. Despite the stop-loss headwinds, Cigna's P/E ratio stands at 17.4 with last-twelve-months revenue of $255.37 billion, and InvestingPro projects fiscal year 2025 EPS at $29.69, with some analysts viewing current guidance as potentially conservative. Key industry factors include rising high-cost drug trends, which Cigna aims to manage through its specialty pharmacy focus, and potential PBM regulations, which management believes the company's flexible business model can adapt to.

Key Decisions for Investors

• Investors should closely monitor the execution of Cigna's stop-loss business turnaround over the next one to two pricing cycles, as successful margin normalization is pivotal for achieving revised earnings targets.
• Evaluate the growth trajectory and margin contribution from the Evernorth segment, particularly the specialty pharmacy businesses Accredo and CuraScript, as these are Cigna's primary long-term value drivers following its strategic divestitures.
• Consider Cigna's current valuation, noted by InvestingPro as potentially undervalued, in conjunction with its significant $7.7 billion share repurchase program and consistent dividend payments, while remaining vigilant about potential impacts from PBM industry regulations and competitive pressures in the managed care sector.